24945-13-9 Usage
Description
2,2-DIMETHYL-TETRAHYDRO-PYRAN-4-OL is a colorless liquid chemical compound belonging to the class of tetrahydro-pyrans. It is characterized by a pleasant odor and is recognized for its safety and low toxicity in consumer products.
Uses
Used in Food and Beverage Industry:
2,2-DIMETHYL-TETRAHYDRO-PYRAN-4-OL is used as a flavor and fragrance ingredient for enhancing the sensory experience of food and beverages, contributing to their overall appeal and consumer satisfaction.
Used in Perfumery:
In the perfume industry, 2,2-DIMETHYL-TETRAHYDRO-PYRAN-4-OL is utilized as a component in creating various scents, adding depth and complexity to perfume compositions.
Used in Detergents and Personal Care Products:
2,2-DIMETHYL-TETRAHYDRO-PYRAN-4-OL is employed in the formulation of detergents and personal care products to provide a pleasant scent and improve the overall user experience.
Used in Medicinal Research:
2,2-DIMETHYL-TETRAHYDRO-PYRAN-4-OL is studied for its potential medicinal properties, such as anti-inflammatory and antioxidant effects, indicating its possible use in the development of pharmaceuticals and health supplements.
Check Digit Verification of cas no
The CAS Registry Mumber 24945-13-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,9,4 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 24945-13:
(7*2)+(6*4)+(5*9)+(4*4)+(3*5)+(2*1)+(1*3)=119
119 % 10 = 9
So 24945-13-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H14O2/c1-7(2)5-6(8)3-4-9-7/h6,8H,3-5H2,1-2H3
24945-13-9Relevant articles and documents
HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS
-
Page/Page column 143, (2019/04/11)
The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 72, (2012/03/09)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o